Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented real-world claims analysis data at ISPOR 2026, revealing the significant clinical and economic burden of fibromyalgia in U.S. adults. The findings underscore high rates of comorbidities, extensive healthcare resource utilization, and widespread reliance on multimodal treatment approaches, emphasizing the urgent need for more effective long-term treatment options as Tonix advances its planned commercial launch of TONMYA.
The retrospective analysis examined more than 261,000 adult fibromyalgia patients and found that over 93% had at least one fibromyalgia-related comorbidity. Insured patients incurred substantial annual healthcare costs driven primarily by inpatient services, illustrating the heavy economic toll of the condition. These data were presented at ISPOR 2026, a leading conference for health economics and outcomes research.
TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg) is Tonix's recently approved flagship medicine and the first new treatment for fibromyalgia in more than 15 years. The company is a fully integrated, commercial-stage biotechnology firm focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra.
Beyond TONMYA, Tonix is maximizing its science through Phase 2 clinical trials evaluating its potential in major depressive disorder and acute stress disorder. The company's CNS portfolio also includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. Additionally, Tonix is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The real-world data presented at ISPOR 2026 highlight the persistent challenges faced by fibromyalgia patients, including high rates of comorbid conditions and reliance on multiple therapies, which collectively drive up healthcare costs. This information is critical for healthcare providers and payers as they seek to improve patient outcomes and manage resource utilization. For investors, the data reinforce the market opportunity for TONMYA as a novel treatment option that could address the unmet needs of millions of fibromyalgia sufferers in the U.S.
Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
